Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care. Guest: Courtney VanHouzen, PharmD PGY-2 Oncology Resident Munson Healthcare, Cowell Family Cancer Center Traverse City, Michigan   “While this [implementation of bispecific T-cell engager therapy] is not an easy thing to make happen, it’s possible for it to be done safely and effectively. That’s what we’re trying to show community cancer centers across the country—that they’re able to offer this therapy to their patients.”   Hear more about this innovation at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota.   Resources: Expanding Access to Cellular and Bispecific Therapies – Considerations and Recommendations by ACCC and SITC  Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumors  Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management